Global News

Aeterna Zentaris announces first patient dosed in phase III endometrial cancer trial

Friday, August 9, 2013 02:05 PM

Aeterna Zentaris has announced the first patient has been recruited and dosed for the phase III ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) trial in women with endometrial cancer resistant to platinum/taxane-based chemotherapy.

More... »

inVentiv Health Clinical expands executive team

Friday, August 9, 2013 02:02 PM

CRO inVentiv Health Clinical has appointed Dawn Anderson president of phase II-IV development, Martin Birkhofer chief medical officer and Richard Shimota chief financial officer.

More... »

Harlan CRS Cytotest Cell Research in EU-NETVAL

Friday, August 9, 2013 01:58 PM

Germany-based Harlan Contract Research Services (CRS) Cytotest Cell Research has been selected for inclusion in the E.U. Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL). EU-NETVAL provides support for the E.U. Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) to develop methods to reduce, refine or replace animals used for scientific purposes.

More... »

NIH, Lacks family share genomic data of HeLa cells

Friday, August 9, 2013 01:17 PM

The National Institutes of Health has reached an understanding with the family of the late Henrietta Lacks to allow biomedical researchers controlled access to the whole genome data of cells derived from her tumor, commonly known as HeLa cells.

More... »

Eli Lilly, TVM fund invests in Ixchelsis

Friday, August 9, 2013 01:14 PM

TVM Life Science Ventures VII, a collaboration between TVM and Eli Lilly to provide venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries, has announced the fund’s second investment in Ixchelsis, a clinical-stage biotechnology startup in the U.K. Ixchelsis plans to develop to proof-of-concept IX-01, an investigational compound, originally discovered at Pfizer’s U.K. R&D site, with the potential to treat the male sexual health indication premature ejaculation.

More... »

GSK launches Action Potential Venture Capital for R&D

Friday, August 9, 2013 01:11 PM

GlaxoSmithKline has announced the launch of Cambridge, Mass.-based Action Potential Venture Capital (APVC), a $50 million strategic venture capital fund that will invest in companies that pioneer bioelectronic medicines and technologies.

More... »

Faculty of 1000 launches database of clinical trials articles

Wednesday, August 7, 2013 02:20 PM

Faculty of 1000, the publisher of a range of services for life scientists and clinicians, has launched F1000Trials, a database designed to enable rapid discovery and understanding of articles about clinical trials. The database is a continually updated, comprehensive database of articles on randomized controlled trials and systematic reviews, drawn from more than 300 general and specialist medical journals.

More... »

Gene by Gene acquires Arpeggi

Wednesday, August 7, 2013 02:18 PM

Gene by Gene, which develops consumer DNA testing products for ancestry and genealogy applications, has acquired Arpeggi, a developer of solutions for genome sequencing, data management and computational analysis.

More... »

CFS Clinical named one of best places to work

Wednesday, August 7, 2013 11:57 AM

Philadelphia Business Journal has named CFS Clinical, a specialty provider focused on the business and financial management activities for clinical trials, one of its Best Places to Work in the Philadelphia region for the second year in a row. The award recognizes the company’s achievements in creating a positive work environment that attracts and retains employees through a combination of benefits, working conditions and company culture.

More... »

The Medicines Company completes Profibrix acquisition on positive trial results

Wednesday, August 7, 2013 11:53 AM

The Medicines Company announced the results of a phase III clinical trial of ProFibrix's lead biologic, Fibrocaps, and, based on its review of those results, completed its previously announced purchase of the company.

More... »